Introduction
============

Cancer is now the major cause of death in developed countries, and its incidence and mortality are increasing for several cancer types, among which the most fatal are liver and pancreatic cancer.[@b1-ott-10-3625] Liver and pancreatic cancer are digestive system cancers, which also includes esophageal cancer (EC), gastric cancer, biliary tract cancer, and colorectal cancer (CRC). Of all the cancers, digestive system cancers demonstrate the highest incidence and death rates.[@b2-ott-10-3625],[@b3-ott-10-3625] Recently, the development of multidisciplinary therapies has significantly improved treatment outcomes, but the overall prognosis for sufferers of digestive system cancers is still poor. Current research is increasingly focused on new immunotherapeutic strategies, which could be a major breakthrough in the field of cancer treatment.[@b4-ott-10-3625] In addition, certain immunologic checkpoint markers have been reported in digestive system cancers, among which PD-L1 is the focus of studies.[@b5-ott-10-3625]

PD-L1, also known as CD274 and B7-H1, is a member of the B7 family of immune regulatory cell surface proteins.[@b6-ott-10-3625] It is commonly upregulated in many different human tumors. The combination of PD-L1 with the receptor PD-1, which has been reported to form and maintain an immunosuppressive microenvironment by suppressing the proliferation of activated T-cells and inducing the apoptosis of T-cells, is considered to be an important immunological escape mechanism that increases the risk of neoplasia.[@b7-ott-10-3625]--[@b10-ott-10-3625] In addition, immune checkpoint blockade using PD-L1 antibodies seems to be one of the most promising immunotherapy approaches.[@b11-ott-10-3625] Although anti-PD-L1 therapies are continuously developing, the prognostic value of PD-L1 is still unclear in various digestive system cancers.

There are many studies that demonstrate the relationship between PD-L1 and survival of patients with different digestive system cancers. But, the conclusions have not reached a consensus and most studies only focused on one cancer type, and did not make an assessment on digestive system cancers. Herein, we conducted a meta-analysis to assess the impact of PD-L1 on the prognosis of digestive system cancers.

Methods
=======

This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Literature search strategy
--------------------------

We searched the PubMed, Embase, and the Chinese National Knowledge Infrastructure databases (up to June 2016) to obtain the relevant articles. The following keywords were used: "PD-L1," "B7-H1," "CD274," "digestive system cancer," "colorectal neoplasms," "esophageal neoplasms," "gastric cancer," "hepatocellular carcinomas," "pancreatic carcinomas," "biliary tract neoplasms," and "prognosis." We also searched the references of the included studies manually to identify relevant publications. Two authors (Cong Dai and Meng Wang) performed the search strategy, and discrepancies were discussed by all the researchers in the group meeting.

Inclusion and exclusion criteria
--------------------------------

No language restrictions were applied. If different studies published by the same investigators have overlapping data, only the most complete one was included.

Studies were included if they fulfilled the following criteria: 1) all selected cancer cases were pathologically confirmed; 2) studies evaluated the relationship of PD-L1 expression in digestive system cancer patients with detailed information of overall survival (OS), disease-free survival (DFS), or recurrence-free survival (RFS); and 3) the study provided a hazard ratio (HR) with the corresponding confidence interval (CI) or sufficient data to calculate it. Articles meeting the following criteria were excluded: 1) unrelated or duplicate publication; 2) nonhuman experiments were performed; 3) case series, case reports, reviews, or studies without original data; 4) crude data were not provided or HRs could not be calculated.

Data extraction
---------------

Two independent researchers (Zhiming Dai and Shuai Lin) extracted the detailed information of included studies with a standardized format. The results were compared, and all the researchers in the group meeting discussed the final decision in case of any discrepancy. The following information was collected: first author surname, year of publication, patient source, number of patients, tumor types, specimen types, method of detection, PD-L1 expression, median follow-up, prognostic outcomes, HR estimate, and HR with its 95% CI. If any of these data were not offered in the study, items were recorded as "--".

Quality assessment
------------------

Methodological quality was assessed using the Newcastle--Ottawa Scale (NOS). The scale includes three domains: selection, comparability, and outcome assessment. Studies with a score of 6--9 were regarded as high quality. Two authors (Cong Dai and Meng Wang) independently graded each study, and all the researchers in the group met to make final decisions regarding any discrepancies.

Statistical analyses
--------------------

The statistical analyses were performed with Stata 12.0 (StataCorp LP, College Station, TX, USA). We computed the pooled HR and its 95% CI to evaluate the relationship between the PD-L1 and the prognosis of patients with digestive system cancer. In addition, prognostic markers were classified into OS, DFS, and RFS. If HRs were provided explicitly in the studies, we used them directly. Otherwise, we calculated the HR from the Kaplan--Meier survival curve or with the available data using methods described by Parmer et al.[@b12-ott-10-3625] Data from the Kaplan--Meier survival curves were read by Engauge Digitizer version 4.1. The *Q* test and the *I*^2^ test were used to evaluate the heterogeneity among studies. If heterogeneity was significant (*P*\<0.1 or *I*^2^\>50%), random-effects model was used.[@b13-ott-10-3625] Otherwise, a fixed-effects Mantel--Haenszel model was applied.[@b14-ott-10-3625] We further conducted subgroup analyses by ethnicity, tumor type, and HR estimate. Sensitivity analysis was performed by omitting individual studies to examine the reliability of the results. Meta-regression analysis was conducted to identify potential factors causing heterogeneity.[@b15-ott-10-3625] Publication bias was assessed using Begg's test, Egger's test, and Begg's funnel plot.[@b16-ott-10-3625],[@b17-ott-10-3625]

Results
=======

Characteristics of included studies
-----------------------------------

We initially identified a total of 343 studies using the search criteria listed earlier. As shown in [Figure 1](#f1-ott-10-3625){ref-type="fig"}, 311 studies were excluded owing to irrelevance to the analysis or lack of the relevant data we needed, or because they were reviews, letters, or animal experiments. Finally, there were 32 studies included in this meta-analysis.[@b18-ott-10-3625]--[@b49-ott-10-3625]

We have summarized the characteristics of the 32 studies in [Table 1](#t1-ott-10-3625){ref-type="table"}. Of the 32 publications, 30 assessed the relationship between PD-L1 and OS in patients with digestive system neoplasms. In addition, eight studies evaluated the relationship between PD-L1 and DFS, and three studies evaluated PD-L1 and RFS. Studies with a total of 7,308 patients, from China, Korea, Japan, the UK, Switzerland, and Germany, were enrolled. In addition, the number of patients in each study ranged from 40 to 1,420. To observe the status of PD-L1 in patients with different cancers, we categorized the cancers into CRC (six studies), EC (five studies), gastric cancer (13 studies), hepatocellular cancer (four studies), pancreatic cancer (three studies), and extrahepatic bile duct cancer (one study). The median positive rate of PD-L1 was 49.6% (range 19.8%--84.8%). The median follow-up times ranged from 20.7 to 75 months. In addition, in methodological quality assessment, all of the studies, which obtained scores ranging from 6 to 9, were considered high quality ([Table 1](#t1-ott-10-3625){ref-type="table"}).

Main meta-analysis results
--------------------------

Overall, there were 30 studies including 6,801 patients concerning the association between OS and PD-L1 expression. The meta-analysis results show that positive expression was associated with significantly poorer OS compared to the negative expression (HR =1.44, 95% CI =1.18--1.76, *P*\<0.001; [Table 2](#t2-ott-10-3625){ref-type="table"} and [Figure 2](#f2-ott-10-3625){ref-type="fig"}). The heterogeneity among studies was statistically significant (*P*\<0.001, *I*^2^=87.8%); therefore, a random-effects model was used.

Three studies with 544 patients reported the RFS. Owing to the significant heterogeneity (*P*=0.023, *I*^2^=68.5%) among these studies, a random-effects model was used. Our results suggested that PD-L1 was not associated with RFS of digestive system cancers (HR =1.27, 95% CI =0.75--2.14, *P*=0.368; [Figure 3](#f3-ott-10-3625){ref-type="fig"}).

As shown in [Table 3](#t3-ott-10-3625){ref-type="table"} and [Figure 4](#f4-ott-10-3625){ref-type="fig"}, there were eight studies comprising 1,566 patients which provided results regarding DFS and PD-L1 expression. The pooled data demonstrated that there was no association between them (HR =0.91, 95% CI =0.61--1.37, *P*=0.657, random-effects model).

Subgroup analyses, sensitivity analyses, and meta-regression in OS
------------------------------------------------------------------

To solve the heterogeneity, we performed subgroup analyses by ethnicity, tumor types, and HR estimate. The subgroup analysis by ethnicity suggested a significant association in studies based on Asians (HR =1.50, 95% CI =1.19--1.89, *P*=0.001) but not among other ethnicities (HR =1.07, 95% CI =0.72--1.58, *P*=0.740). In the subgroup analysis by tumor types, significant associations were found in gastric cancer (HR =1.43, 95% CI =1.05--1.94, *P*=0.021) and pancreatic carcinoma (HR =2.64, 95% CI =1.78--3.93, *P*\<0.001). For HR estimation, subgroup analysis showed that the overall HR estimate with univariate analysis was 1.64 (95% CI =1.21--2.23, *P*=0.001; [Table 2](#t2-ott-10-3625){ref-type="table"}). Meanwhile, it is worth mentioning that heterogeneity among most of the subgroups was statistically significant (*P*\>0.1 or *I*^2^\>50%).

The included studies were sequentially removed to investigate whether any single study has an influence on the pooled results. As shown in [Figure 5](#f5-ott-10-3625){ref-type="fig"}, the stable pooled HR was not significantly affected by any individual study.

The meta-regression was performed to identify the source of the heterogeneity. We analyzed possible factors including publication year, ethnicity, number of patients, tumor types, and PD-L1 expression. The results confirmed that the number of patients per study might be a major source of heterogeneity ([Table 4](#t4-ott-10-3625){ref-type="table"}).

Subgroup analyses in DFS
------------------------

We also performed subgroup analysis for ethnicity, tumor types, and HR estimate among studies focus on DFS. Only the subgroup analysis for the HR estimate showed a significant association with DFS based on multivariate analysis (HR =0.75, 95% CI =0.59--0.97, *P*=0.026; [Table 3](#t3-ott-10-3625){ref-type="table"}).

Publication bias
----------------

We performed Begg's and Egger's tests to identify whether any publication bias existed in the published literature in this meta-analysis. Publication bias was observed among studies reporting OS (*P*=0.498, 0.003), but no publication bias was found among studies reporting DFS (*P*=0.230, 0.330) or RFS (*P*=0.308, 0.328). The Begg's plots for the effect of PD-L1 expression on OS are shown in [Figure 6](#f6-ott-10-3625){ref-type="fig"}.

Discussion
==========

Recently, according to many reports, cancer cells are able to use immunosuppressive molecules to their advantage via inhibiting antitumor lymphocytes, thus evading destruction by the immune system. Therefore, immunotherapy is now considered a novel method of cancer treatment.[@b50-ott-10-3625] Cancer immunotherapy is a revolutionary cancer treatment targeting the immune checkpoint receptors such as PD-L1. PD-L1 antibodies have been proved to exert clinical activity in more than 15 types of cancers including EC, gastric cancer, hepatocellular cancer, and CRC.[@b51-ott-10-3625] These studies suggested that PD-L1 may be a prognostic biomarker and a potential target of treatment in digestive system cancers. In this meta-analysis, we investigated the association between the expression of PD-L1 and the prognosis of digestive system cancer patients by analyzing the published data.

Our results showed that PD-L1 overexpression was significantly associated with shorter OS. These results indicated that PD-L1 can serve as a novel parameter for prognostication and a promising target for anticancer therapy in digestive system cancers. When extended to subgroup analysis, no clear correlation between PD-L1 expression and OS was found in non-Asian, CRC, EC, and hepatocellular carcinoma (HC) patients, possibly owing to the insufficiently large sample size. Therefore, it is necessary for better designed studies with more patients to prove or to retort our results in the future.

There was a significant heterogeneity across the included studies. However, subgroup analyses of ethnicity, tumor types, and the methods used to estimate the HR failed to identify its source. The sensitivity analyses showed that the stable pooled HR was not significantly affected by each individual study. The meta-regression confirmed that the number of patients might be a major source of heterogeneity. However, the meta-regression adjusted *R*^2^ value of the number of patients is just 15.78% (data not shown), which could only explain a small part of heterogeneity source. Therefore, it is likely that the heterogeneity is due to the differences in the baseline characteristics of patients, the immunohistochemical methods, and the baseline referring to positive/high PD-L1 expression. However, because of lacking clinical data in these aspects, we cannot determine their contribution to the heterogeneity among studies.

Previously, some meta-analyses have been conducted to study the association between PD-L1 and some cancers in the digestive system. Huang et al[@b52-ott-10-3625] identified nine studies that involved 2,500 gastrointestinal tract cancer patients, and reported that PD-L1 is a prognostic risk factor for gastrointestinal tract cancer. The study by Wu et al,[@b53-ott-10-3625] which included seven studies with 687 patients, showed that positive PD-L1 expression status in tumor cells was associated with worse 5-year OS of EC, gastric cancer, and CRC. Compared with these studies, our meta-analysis has some differences and advantages. First of all, our study is the first meta-analysis to estimate the role of PD-L1 in the prognosis of digestive system cancers. Second, we not only analyzed OS but also evaluated DFS and RFS, which contributed to a comprehensive understanding of the issue. Third, our conclusion is more reliable because several new studies fulfilling the inclusion criteria have been included.

We attempted to conduct a comprehensive analysis of PD-L1 and prognosis of digestive system cancers, but it should be recognized that there are still some limitations in our study. First, some survival data were not reported directly; therefore, an indirect method was used to extract data from the Kaplan--Meier survival curves, which may affect the accuracy of the original data. Second, publication bias was observed among studies reporting OS. The reason may be that studies with positive results were published more easily. Third, we cannot recognize the association between subgroups of RFS and PD-L1 expression due to lack of data. More importantly, the PD-L1 expression level measured using immunohistochemistry might show high variability between studies. Hence, a baseline for positive/high PD-L1 expression should be established.

Conclusion
==========

We found that PD-L1 expression indicated poor OS outcomes. We indicated that PD-L1 may serve as a prognostic indicator and a potential novel target for treatment in digestive system cancers.
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![Flowchart of the selection of the studies in the meta-analysis.\
**Abbreviation:** ELISA, enzyme-linked immunoabsorbent assay.](ott-10-3625Fig1){#f1-ott-10-3625}

![Forest plot of HR for the association of PD-L1 overexpression and OS.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; OS, overall survival.](ott-10-3625Fig2){#f2-ott-10-3625}

![Forest plot of HR for the association of PD-L1 overexpression and RFS.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; RFS, recurrence-free survival.](ott-10-3625Fig3){#f3-ott-10-3625}

![Forest plot of HR for the association of PD-L1 overexpression and DFS.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.](ott-10-3625Fig4){#f4-ott-10-3625}

![Sensitivity analysis of pooled HRs on the association between PD-L1 expression and OS.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; OS, overall survival.](ott-10-3625Fig5){#f5-ott-10-3625}

![Funnel plots of publication bias for all the included studies reported with OS.\
**Abbreviations:** HR, hazard ratio; OS, overall survival; SE, standard error.](ott-10-3625Fig6){#f6-ott-10-3625}

###### 

Characteristics of included studies for meta-analyses

  First author                      Year   Patient source   No of patients   Tumor types         Specimen   Method   PD-L1 expression (%)   Median (range) follow-up (months)   Outcome   M/U   HR (95% CI)                             NOS score
  --------------------------------- ------ ---------------- ---------------- ------------------- ---------- -------- ---------------------- ----------------------------------- --------- ----- --------------------------------------- -----------
  Dunne et al[@b22-ott-10-3625]     2016   UK               424              CRC                 Tissue     IHC      19.8                   --                                  RFS       M     0.76 (0.39--1.45)                       7
  Wang et al[@b20-ott-10-3625]      2016   China            262              CRC                 Tissue     IHC      20.6                   43.5 (21--68)                       OS        M     1.90 (0.88--4.14)                       7
  Yuan et al[@b18-ott-10-3625]      2016   China            165              GC                  Tissue     IHC      33.9                   63.1                                OS        U     1.15 (0.80--1.67)                       6
  Dong et al[@b23-ott-10-3625]      2016   China            547              GC                  Tissue     IHC      84.8                   --                                  OS        U     0.74 (0.49--1.10)                       7
  Böger et al[@b26-ott-10-3625]     2016   Germany          465              GC                  Tissue     IHC      23.9                   20.7 (0.2--109)                     OS        M     0.75 (0.58--0.97)                       9
  Wang et al[@b19-ott-10-3625]      2016   China            105              GC                  Tissue     IHC      49.5                   42                                  OS        U     1.93 (1.12--3.32)                       8
  Chen et al[@b25-ott-10-3625]      2016   China            536              EC                  Tissue     IHC      41.4                   32.7 (1.0--88.7)                    OS; DFS   M     0.83 (0.59--1.18); 0.80 (0.55--1.17)    9
  Chen et al[@b24-ott-10-3625]      2016   China            162              EC                  Tissue     IHC      45                     --                                  OS        U     3.90 (2.51--6.05)                       8
  Leng et al[@b21-ott-10-3625]      2016   China            106              EC                  Tissue     IHC      53.8                   55                                  OS        U     1.39 (0.65--2.99)                       7
  Lim et al[@b31-ott-10-3625]       2015   Korea            83               Bile duct cancer    Tissue     IHC      68                     27--69                              DFS       M     0.55 (0.27--1.12)                       7
  Lim et al[@b32-ott-10-3625]       2015   Korea            73               EC                  Tissue     IHC      56.2                   --                                  OS; DFS   M     2.29 (1.12--4.69); 1.46 (0.75--2.84)    7
  Tamura et al[@b29-ott-10-3625]    2015   Japan            431              GC                  Tissue     IHC      29.7                   34                                  OS        M     1.50 (1.02--2.19)                       6
  Zhang et al[@b27-ott-10-3625]     2015   China            132              GC                  Tissue     IHC      50.8                   66.0 (3.0--153.0)                   OS        M     2.70 (1.47--4.95)                       8
  Qing et al[@b30-ott-10-3625]      2015   China            107              GC                  Tissue     IHC      50.5                   42                                  OS        U     2.01 (1.09--3.70)                       7
  Eto et al[@b35-ott-10-3625]       2015   Japan            105              GC                  Tissue     IHC      24.8                   34 (7--87)                          OS; DFS   U     2.26 (0.61--8.33); 1.88 (0.95--3.71)    7
  Geng et al[@b34-ott-10-3625]      2015   China            100              GC                  Tissue     IHC      65                     \>60                                OS        M     2.12 (1.59--2.34)                       8
  Kan and Dong[@b33-ott-10-3625]    2015   China            128              HC                  Tissue     IHC      82.03                  10                                  OS        U     2.12 (1.32--3.38)                       7
  Umemoto et al[@b28-ott-10-3625]   2015   Japan            80               HC                  Tissue     IHC      46.3                   80                                  OS; RFS   U     1.27 (0.54--3.01); 1.45 (0.80--2.63)    8
  Kim et al[@b37-ott-10-3625]       2014   Korea            243              GC                  Tissue     IHC      56.4                   74 (0--123)                         OS; DFS   M     0.65 (0.42--1.02); 0.58 (0.37--0.91)    9
  Hou et al[@b38-ott-10-3625]       2014   China            111              GC                  Tissue     IHC      63.1                   7--48                               OS        U     1.47 (0.60--3.57)                       9
  Liang et al[@b36-ott-10-3625]     2014   China            185              CRC                 Tissue     IHC      55.1                   60                                  OS; DFS   U     0.58 (0.37--0.84); 0.55 (0.36--0.82)    8
  Song et al[@b39-ott-10-3625]      2013   China            347              CRC                 Tissue     IHC      --                     32.4 (1.2--109.2)                   OS        M     1.17 (0.70--1.98)                       7
  Droeser et al[@b41-ott-10-3625]   2013   Switzerland      1,420            CRC                 Tissue     IHC      37                     --                                  OS        M     0.92 (0.88--0.96)                       6
  Shi et al[@b40-ott-10-3625]       2013   China            143              CRC                 Tissue     IHC      44.8                   --                                  OS        U     2.61 (1.01--3.58)                       8
  Loos et al[@b43-ott-10-3625]      2011   Germany          101              Barrett carcinoma   Tissue     IHC      36.6                   75 (7--209)                         OS; DFS   U     2.92 (1.50--5.66); 2.99 (1.61--5.64)    8
  Zeng et al[@b42-ott-10-3625]      2011   China            141              HC                  Tissue     IHC      51.8                   23 (6--36)                          OS        M     0.37 (0.19--0.77)                       7
  Wang et al[@b44-ott-10-3625]      2010   China            81               PC                  Tissue     IHC      49.4                   24 (8--39)                          OS        U     2.56 (1.44--4.56)                       6
  Gao et al[@b45-ott-10-3625]       2009   China            240              HC                  Tissue     IHC      25                     --                                  OS; DFS   U     0.62 (0.40--0.96); 0.56 (0.37--0.85)    8
  Chen et al[@b46-ott-10-3625]      2009   China            40               PC                  Tissue     IHC      45                     58.5 (5--122)                       OS; RFS   M     3.23 (1.34--7.80); 4.33 (1.53--12.28)   7
  Nomi et al[@b48-ott-10-3625]      2007   Japan            51               PC                  Tissue     IHC      39.2                   22 (3--91)                          OS        U     2.44 (1.22--4.89)                       6
  Sun et al[@b47-ott-10-3625]       2007   China            92               GC                  Tissue     IHC      46.7                   6--31                               OS        U     2.10 (1.09--4.05)                       7
  Wu et al[@b49-ott-10-3625]        2006   China            102              GC                  Tissue     IHC      42.2                   42                                  OS        U     2.06 (0.99--4.28)                       6

**Abbreviations:** CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; EC, esophageal carcinoma; GC, gastric cancer; HC, hepatocellular carcinoma; HR, hazard ratio; IHC, immunohistochemistry; M, multivariate; NOS, Newcastle--Ottawa Scale; OS, overall survival; PC, pancreatic carcinoma; RFS, recurrence-free survival; U, univariate.

###### 

Main meta-analysis results for OS

  Analysis                 No of studies   No of patients   Model    HR (95% CI)             *P*-value   Heterogeneity   
  ------------------------ --------------- ---------------- -------- ----------------------- ----------- --------------- -------
  OS                       30              6,801            Random   **1.44 (1.18--1.76)**   0.000       87.8            0.000
  Ethnicity                                                                                                              
   Asian                   27              4,815            Random   **1.50 (1.19--1.89)**   0.001       82.0            0.000
   Non-Asian               3               1,98             Random   1.07 (0.72--1.58)       0.740       85.7            0.001
  Tumor types                                                                                                            
   CRC                     5               2,357            Random   1.15 (0.76--1.72)       0.511       79.7            0.001
   GC                      13              2,705            Random   **1.43 (1.05--1.94)**   0.021       83.6            0.000
   EC                      5               978              Random   1.96 (0.97--3.97)       0.061       88.1            0.000
   HC                      4               589              Random   0.89 (0.40--1.97)       0.776       86.5            0.000
   PC                      3               172              Fixed    **2.64 (1.78--3.93)**   0.00        0.0             0.878
  HR estimate                                                                                                            
   Multivariate analysis   12              4,190            Random   1.22 (0.92--1.63)       0.171       90.5            0.000
   Univariate analysis     18              2,611            Random   **1.64 (1.21--2.23)**   0.001       80.4            0.000

**Note:** Bold means that there was significant association between PD-L1 expression and the items of "Analysis".

**Abbreviations:** CI, confidence interval; CRC, colorectal cancer; EC, esophageal carcinoma; GC, gastric cancer; HC, hepatocellular carcinoma; HR, hazard ratio; OS, overall survival; PC, pancreatic carcinoma.

###### 

Main meta-analysis results for DFS

  Analysis                 No of studies   No of patients   Model    HR (95% CI)             *P*-value   Heterogeneity   
  ------------------------ --------------- ---------------- -------- ----------------------- ----------- --------------- -------
  DFS                      8               1,566            Random   0.91 (0.61--1.37)       0.657       80.1            0.000
  Ethnicity                                                                                                              
   Asian                   7               1,465            Random   0.76 (0.56--1.05)       0.094       64.2            0.010
   Non-Asian               1               101              --       0.97 (0.62--1.52)       0.001       --              --
  Tumor types                                                                                                            
   GC                      2               348              Random   1.01 (0.32--3.21)       0.981       87.5            0.005
   EC                      3               710              Random   1.47 (0.66--3.30)       0.346       84.5            0.002
  HR estimate                                                                                                            
   Multivariate analysis   4               935              Fixed    **0.75 (0.59--0.97)**   0.026       49.5            0.115
   Univariate analysis     4               631              Random   1.11 (0.50--2.46)       0.805       89.6            0.000

**Note:** Bold means that there was significant association between PD-L1 expression and the items of "Analysis".

**Abbreviations:** CI, confidence interval; DFS, disease-free survival; EC, esophageal carcinoma; GC, gastric cancer; HR, hazard ratio.

###### 

Meta-regression analyses of potential source of heterogeneity

  Heterogeneity factors   Coefficient   SE      *Z*     *P*-value   95% CI   
  ----------------------- ------------- ------- ------- ----------- -------- --------
  Publication year        −0.024        0.038   −0.63   0.536       −0.102   0.054
  Ethnicity               −0.246        0.351   −0.70   0.489       −0.966   0.473
  Number of patients      −0.001        0.000   −2.33   0.028       −0.002   −0.000
  Tumor types             0.089         0.094   0.94    0.353       −1.039   0.282
  PD-L1 expression        0.001         0.008   0.08    0.938       −0.015   0.016

**Abbreviations:** CI, confidence interval; LL, lower limit; SE, standard error; UL, upper limit.
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